Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TAK
stocks logo

TAK

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
1.16T
+1.37%
--
--
1.09T
+3.5%
--
--
1.15T
+3.87%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -6.61%.
Revenue Estimates for FY2026
Revise Downward
down Image
-1.23%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-17.2%
In Past 3 Month
Stock Price
Go Down
down Image
-6.61%
In Past 3 Month
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.280
sliders
Low
18.00
Averages
18.00
High
18.00
Current: 14.280
sliders
Low
18.00
Averages
18.00
High
18.00
JPMorgan
Neutral
maintain
$34 -> $35
2025-09-09
Reason
JPMorgan
Price Target
$34 -> $35
2025-09-09
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm sees see alixorexton as well-positioned in narcolepsy type I based on detailed results from the Phase II Vibrance-1 study. Alixorexton delivered a profile broadly inline with expectations with efficacy that generally looks better than Takeda's (TAK) Phase III data for oveporexton, the analyst tells investors in a research note. JPMorgan upped its probability of sucess for alixorexton in narcolepsy type I to 75% from 70% following the data.
Needham
Buy
downgrade
$45 -> $43
2025-09-09
Reason
Needham
Price Target
$45 -> $43
2025-09-09
downgrade
Buy
Reason
Needham lowered the firm's price target on Alkermes (ALKS) to $43 from $45 and keeps a Buy rating on the shares following Phase 2 data from the Vibrance-1 study. The firm reduced aliorexton's peak market share in narcolepsy type I by 10% to reflect its safety profile of blurred vision adverse events. The events may dissuade some physicians from using aliorexton as their first choice, especially in narcolepsy type I, given Takeda's (TAK) first-to-market position, the analyst tells investors in a research note. However, Needham continues to see valuation upside for Alkermes, believing alixorexton can have meaningful market share.
BofA
BofA
Neutral
maintain
2025-07-21
Reason
BofA
BofA
Price Target
2025-07-21
maintain
Neutral
Reason
BofA keeps a Neutral rating on Alkermes (ALKS) after the company reported Phase 2 results from the Vibrance-1 study evaluating its orexin-receptor 2 agonist in narcolepsy type1 patients. The study validates ALKS2680 as an active drug in narcolepsy, the analyst tells investors in a research note. However, the press release provided limited details on effect size and safety, which leaves outstanding questions such as strength of the cataplexy data and competitiveness versus Takeda's (TAK) TAK-861, contends BofA. The firm cites the limited data disclosure to the stock's selloff today. Alkermes in morning trading is down 7% to $27.09.
Needham
Needham
Buy
maintain
$270 -> $300
2025-05-29
Reason
Needham
Needham
Price Target
$270 -> $300
2025-05-29
maintain
Buy
Reason
Needham raised the firm's price target on Veeva (VEEV) to $300 from $270 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. Despite concerns related to Salesforce's (CRM) recent announcement of winning Takeda (TAK) for CRM, Veeva is executing well on the conversion to Vault, with over 200 customers expected to be live by company's summit next spring, the analyst tells investors in a research note. Veeva also believes that custom builds for companies like Takeda may prove too costly, leading the company to see opportunities for competitive win backs, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 22.65, compared to its 5-year average forward P/E of 26.96. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.96
Current PE
22.65
Overvalued PE
39.83
Undervalued PE
14.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
9.39
Current EV/EBITDA
9.40
Overvalued EV/EBITDA
10.54
Undervalued EV/EBITDA
8.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.59
Current PS
1.53
Overvalued PS
1.74
Undervalued PS
1.44
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TAK News & Events

Events Timeline

(ET)
2025-11-21
09:11:09
FDA probes death linked to Adzynma therapy
select
link
2025-11-07 (ET)
2025-11-07
11:06:30
Takeda unveils preliminary findings from Phase 1b trial of mezagitamab
select
2025-11-03 (ET)
2025-11-03
07:20:09
Takeda concludes seven-year Phase 3 TIDES study of Qdenga
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
08:13 AMNewsfilter
Innovent Biologics and Takeda Finalize $11.4 Billion Global Collaboration
  • Collaboration Agreement Finalized: Innovent Biologics and Takeda's global strategic collaboration has become effective, aiming to accelerate the development of next-generation immuno-oncology and antibody-drug conjugate therapies, which is expected to significantly enhance both companies' competitiveness in the global cancer treatment market.
  • Substantial Upfront Investment: Takeda will pay Innovent an upfront payment of $1.2 billion, including a $100 million equity investment, which will provide robust support for Innovent's R&D and market promotion efforts.
  • Milestone Payment Potential: Innovent is eligible for up to $10.2 billion in milestone payments from the development and sales of IBI363, IBI343, and IBI3001, further strengthening its financial position and driving future R&D activities.
  • Global Market Expansion: This collaboration grants Takeda exclusive commercialization rights for IBI363 and IBI343 outside Greater China, marking a significant step in Innovent's international market expansion and enhancing its global influence.
[object Object]
Preview
7.5
08:00 AMNASDAQ.COM
Innovent and Takeda Finalize $11.4 Billion Partnership to Develop Next-Generation IO and ADC Treatments

  • Collaboration Announcement: Innovent Biologics has finalized a global strategic collaboration with Takeda to enhance the development and commercialization of its immuno-oncology and antibody-drug conjugate therapies, including IBI363 and IBI343.

  • Co-Development and Commercialization: The agreement allows for co-development of IBI363 in the U.S. with shared manufacturing rights, while Takeda gains exclusive rights for IBI343 and an option for IBI3001 outside Greater China.

  • Financial Terms: Takeda will make an upfront payment of $1.2 billion to Innovent, which includes a $100 million equity investment, with potential milestone payments bringing the total deal value to approximately $11.4 billion.

  • Royalty and Profit Sharing: Innovent will receive royalties for each molecule outside Greater China, and profits and losses for IBI363 in the U.S. will be shared on a 40/60 basis between Innovent and Takeda.

[object Object]
Preview
7.5
07:42 AMPRnewswire
Innovent Biologics Closes $11.4 Billion Strategic Collaboration with Takeda
  • Collaboration Agreement Finalized: Innovent Biologics and Takeda's global strategic collaboration has officially closed, with a total deal value of up to $11.4 billion, showcasing the strong synergistic potential in the field of immuno-oncology.
  • Significant Upfront Investment: Takeda will pay Innovent an upfront payment of $1.2 billion, including a $100 million equity investment, indicating strong confidence in Innovent's future growth prospects.
  • Milestone Payment Opportunities: Innovent is eligible for up to $10.2 billion in development and sales milestone payments, which will significantly enhance its liquidity and support further R&D efforts.
  • Market Expansion Potential: This collaboration will expedite the global commercialization of Innovent's next-generation therapies like IBI363 and IBI343, expected to significantly boost its competitiveness in the international biopharmaceutical market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 14.28 USD — it has decreased -0.21 % in the last trading day.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

arrow icon

What is the price predicton of TAK Stock?

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.11T USD, decreased -5.38 % YoY.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -7.48 USD, decreased -113.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Takeda Pharmaceutical Co Ltd (TAK)'s fundamentals?

The market is revising Downward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -6.61%.
arrow icon

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of December 05 2025.

arrow icon

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 45.44B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free